BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26878872)

  • 21. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
    Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
    J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
    Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
    Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].
    Gao P; Li Q; Wang Z; Yan F; Lu C; Cao X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):628-31. PubMed ID: 25297597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C; Canal F; Parolini C; Andreoli A; Ambrosetti A; Krampera M; Lestani M; Pizzolo G; Chilosi M
    Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
    Weng Y; Gao ZF; Liu K; Zhang WJ; Ke XY; Li M
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):681-3. PubMed ID: 16202261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.
    Wang X; Boddicker RL; Dasari S; Sidhu JS; Kadin ME; Macon WR; Ansell SM; Ketterling RP; Rech KL; Feldman AL
    Hum Pathol; 2017 Jun; 64():19-27. PubMed ID: 28153507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma.
    Ye H; Lu L; Ge B; Gao S; Ma Y; Liang B; Yu K; Yang K
    Int J Clin Exp Pathol; 2015; 8(10):13043-50. PubMed ID: 26722499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.
    Kerbauy FR; Colleoni GW; Saad ST; Regis Silva MR; Correa Alves A; Aguiar KC; Albuquerque DM; Kobarg J; Seixas MT; Kerbauy J
    Leuk Lymphoma; 2004 Oct; 45(10):2071-8. PubMed ID: 15370252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
    Hou Y; Wang HQ; Ba Y
    Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
    Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.